SG11201809184VA - Crystal polymorphism of kcnq2-5 channel activator - Google Patents

Crystal polymorphism of kcnq2-5 channel activator

Info

Publication number
SG11201809184VA
SG11201809184VA SG11201809184VA SG11201809184VA SG11201809184VA SG 11201809184V A SG11201809184V A SG 11201809184VA SG 11201809184V A SG11201809184V A SG 11201809184VA SG 11201809184V A SG11201809184V A SG 11201809184VA SG 11201809184V A SG11201809184V A SG 11201809184VA
Authority
SG
Singapore
Prior art keywords
crystal
kcnq2
polymorphism
crystal polymorphism
channel activator
Prior art date
Application number
SG11201809184VA
Inventor
Kentaro Yashiro
Hideomi Kijima
Daisuke Wakamatsu
Tetsuji Saito
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of SG11201809184VA publication Critical patent/SG11201809184VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, 5 stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to 10 KCNQ2-5 channels.
SG11201809184VA 2016-04-22 2017-04-21 Crystal polymorphism of kcnq2-5 channel activator SG11201809184VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016086239 2016-04-22
PCT/JP2017/016109 WO2017183725A1 (en) 2016-04-22 2017-04-21 Crystal polymorphism of kcnq 2-5 channel activator

Publications (1)

Publication Number Publication Date
SG11201809184VA true SG11201809184VA (en) 2018-11-29

Family

ID=60116201

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809184VA SG11201809184VA (en) 2016-04-22 2017-04-21 Crystal polymorphism of kcnq2-5 channel activator

Country Status (15)

Country Link
US (1) US20190135755A1 (en)
EP (1) EP3447047A1 (en)
JP (1) JP6265313B1 (en)
KR (1) KR20180135448A (en)
CN (1) CN109071441A (en)
AU (1) AU2017254257A1 (en)
BR (1) BR112018071654A2 (en)
CA (1) CA3021624A1 (en)
IL (1) IL262439A (en)
MX (1) MX2018012898A (en)
PH (1) PH12018502228A1 (en)
RU (1) RU2018136892A (en)
SG (1) SG11201809184VA (en)
WO (1) WO2017183725A1 (en)
ZA (1) ZA201807006B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA89503C2 (en) * 2004-09-13 2010-02-10 Х. Луннбек А/С Substituted aniline derivatives
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2013156154A1 (en) * 2012-04-18 2013-10-24 Grünenthal GmbH Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
BR112015012418A2 (en) * 2012-11-28 2017-07-11 Gruenenthal Gmbh specific carboxamides as modulators of kcnq2 / 3
RU2712163C2 (en) * 2014-10-24 2020-01-24 Оно Фармасьютикал Ко., Лтд. Activator of kcnq2-5 channels

Also Published As

Publication number Publication date
CA3021624A1 (en) 2017-10-26
ZA201807006B (en) 2019-07-31
EP3447047A4 (en) 2019-02-27
IL262439A (en) 2018-12-31
CN109071441A (en) 2018-12-21
PH12018502228A1 (en) 2019-07-08
JP6265313B1 (en) 2018-01-24
US20190135755A1 (en) 2019-05-09
AU2017254257A1 (en) 2018-11-15
EP3447047A1 (en) 2019-02-27
MX2018012898A (en) 2019-01-30
BR112018071654A2 (en) 2019-02-19
WO2017183725A1 (en) 2017-10-26
RU2018136892A (en) 2020-05-22
JPWO2017183725A1 (en) 2018-04-26
KR20180135448A (en) 2018-12-20

Similar Documents

Publication Publication Date Title
CY1124848T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZD9291
PH12018501226A1 (en) Methods for treating huntingtons disease
EA201892838A1 (en) NEW PIPERIDINILIC DERIVATIVES, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
BR112016001678A2 (en) COMPOSITION, METHOD OF MANUFACTURE OF A TABLET, TABLET, UNIT DOSAGE FORM, ARTICLE OF MANUFACTURE, AND, USE OF A COMPOSITION, TABLET OR UNIT DOSAGE FORM
MX2018009459A (en) Sulfonamide derivative and pharmaceutical composition containing same.
EA201790726A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS
EA201691600A1 (en) DIHYDROPYRIDINOUS INHIBITORS MGAT2 FOR USE IN THE TREATMENT OF METABOLIC DISORDERS
EA201700019A1 (en) HIGHLY PURE ORIENTATION AND METHOD FOR ITS OBTAINING
EA201890534A1 (en) NEW ANNELED PHENOXYCETAMIDES
MY176618A (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)- n,2-dimethylbenzofuran-3-carboxamide
WO2018125880A8 (en) Nrf2 activator
PH12016502568A1 (en) Novel heterocyclic compound
WO2018218161A3 (en) Methods and compositions for regulating glucose homeostasis
PH12017501335B1 (en) Novel salt of fused pyrimidine compound and crystal thereof
SG11201809184VA (en) Crystal polymorphism of kcnq2-5 channel activator
WO2014197536A3 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof
AR112440A1 (en) CRYSTAL FORM OF A BCL-2 INHIBITOR, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
WO2016092560A3 (en) Dual release bilayer tablets comprising metformin
TH1701001398A (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-il compounds And using it as a SGRM controller
SG11201909483WA (en) Crystals of pyranodipyridine compound
AR110451A1 (en) TRICYCLIC COMPOUND THAT HAS SULFINYL AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
TH168624A (en) Glucopyranosil-substrate derivatives Indole-urea And the use of those substances As an SGLT inhibitor
AR107790A1 (en) SOLID FORMS OF AN ACCESS INHIBITING HEROPIRIMIDINDIONA AND PRODUCTION METHODS OF THE SAME